US Congress 'May' Finish Diagnostic Regulatory Reforms By End Of 2017, Rep. Burgess Says
Congress may complete work they started in March on the 'Diagnostic Accuracy and Innovation Act' by the end of this legislative year, Rep. Michael Burgess, R-Texas, said. But if not, almost certainly it will be addressed by the end of 2018, before the 115th Congress adjourns.
You may also be interested in...
A US FDA spending bill approved by the House Appropriations Committee July 12 would halt finalization of the agency's draft 2014 laboratory developed test guidance, recommending that FDA let Congress write its own bill directing any LDT regulation – but FDA already essentially handed the LDT reins to lawmakers last January.
When the House Appropriations Committee takes up the US FDA funding bill for 2018, report language would "prevent the agency from finalizing a guidance on regulating laboratory developed tests," Rep. Rosa DeLauro said at a June 28 Ag/FDA subcommittee markup. The House bill, while maintaining FDA discretionary funding at its prior-year $2.8bn level, also fully appropriates user fee authorizations agreed to by Senate and House Committees in FDA Reauthorization bills in May and June, respectively.
House Energy and Commerce Committee members added a slate of industry-favored device amendments into the FDA Reauthorization Act before sending the bill to the chamber floor, including reforms targeting device accessories, medical imaging and post-market surveillance.